Gout

Patients with type 2 diabetes who receive sodium-glucose transport protein 2 inhibitors may have a lower risk for gout compared with those using dipeptidyl peptidase 4 inhibitors, according to data published in JAMA Network Open.

New insight into the top reasons for COVID-19 vaccine hesitancy among underrepresented populations with rheumatic diseases was the top story in rheumatology last week.

Adding colchicine to the standard care regimen for COVID-19 fails to decrease disease severity or reduce the risk for death in hospitalized patients, according to a meta-analysis published in RMD Open.

A median of just 16.2% of adults with arthritis attended a self-management class in 2019, while that same year 69.3% received counseling for physical activity from their provider, according to CDC researchers.

Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy, according to data presented at ACR Convergence 2021.

For patients with advanced chronic kidney disease, gout can significantly increase health care utilization and comorbidities, according to a study presented at ASN Kidney Week.

Pegloticase decreased serum urate in patients with uncontrolled gout who previously received a kidney transplant and were treated with more than one immunosuppressive therapy to protect against organ rejection.

In this video, Craig A. Shadur, MD, a transplant nephrologist from Des Moines, Iowa, discussed the use of pegloticase for patients with kidney transplants.

In this video from ASN Kidney Week, Anthony Bleyer, MD, discussed his large cohort study on risk factors and outcomes of gout in patients on dialysis.

Patients with rheumatoid arthritis, gout, polydermatomyositis, vasculitis and those with multiple rheumatic diseases were at greatest risk for breakthrough COVID-19 infection, despite full or partial vaccination vs. those without rheumatic disease.